Skip to content

Nexvet Biopharma plc

CIK 0001618561

← back to feed
Revenue (TTM)
$25K
+92.3% YoY Q3 Apr 2017
Net Income (TTM)
−$22.27M
+30.9% YoY Q3 Apr 2017
EPS Diluted (TTM)
—
Q3 Apr 2017
Gross Margin
—
Q3 Apr 2017
Operating Margin
-95,948.0%
Q3 Apr 2017
Net Margin
-89,084.0%
Q3 Apr 2017
Free Cash Flow (TTM)
—
Q3 Apr 2017
Cash
$14.52M
Q3 Apr 2017
Total Debt
—
Q3 Apr 2017
Shares Outstanding
11.92M sh
Q3 Apr 2017

Revenue & Net Income

Margins

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings